Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152· Phase 3· Immuneering Corporation· Source
Contact: Study Team
Recruiting
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
NCT07326566· Phase 2· Black Diamond Therapeutics, Inc.· Source
Contact: Anais Vega
Recruiting
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676· Phase 1/2· Astellas Pharma Global Development, Inc.· Source
Contact: Astellas Pharma Global Development, Inc
Recruiting
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT07061977· Phase 3· National Cancer Institute (NCI)· Source
Contact: Yonatan Weiss (principal investigator)
Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NCT07097142· Phase 3· NRG Oncology· Source
Contact: Adeel Kaiser (principal investigator)
Recruiting
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
NCT07022483· Phase 3· Daiichi Sankyo· Source
Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328· Phase 3· NRG Oncology· Source
Contact: Michael D. Chuong (principal investigator)
Recruiting
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
NCT06577441· Phase 2· National Cancer Institute (NCI)· Source
Contact: Firas El Chaer (principal investigator)
Recruiting
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
NCT06672146· Phase 2· National Cancer Institute (NCI)· Source
Contact: Firas El Chaer (principal investigator)
Recruiting
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
NCT06498635· Phase 3· National Cancer Institute (NCI)· Source
Contact: Bruna Pellini Ferreira (principal investigator)
Recruiting
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Rohan Garje (principal investigator)
Recruiting
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
NCT06500481· Phase 3· NRG Oncology· Source
Contact: Matthew D. Hall (principal investigator)
Recruiting
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
NCT06513962· Phase 3· Children's Oncology Group· Source
Contact: Doured Daghistani (principal investigator)
Active, not recruiting
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563· Phase 3· NovoCure GmbH· Source
Recruiting
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774· Phase 3· Incyte Corporation· Source
Active, not recruiting
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· Phase 3· NRG Oncology· Source
Recruiting
A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers
NCT05893888· Phase 2/3· Privo Technologies· Source
Contact: Alessandra Villa, DDS Chief of oral medicine, oral oncology and dentistry at Miami C
Recruiting
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
NCT06377852· Phase 3· American Society of Clinical Oncology· Source
Contact: Kristianne Enriquez
Recruiting
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study
NCT06410209· Phase 2· Children's Oncology Group· Source
Contact: Matthew D. Hall (principal investigator)
Recruiting
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
NCT06317649· Phase 2· National Cancer Institute (NCI)· Source
Contact: Firas El Chaer (principal investigator)
Recruiting
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
NCT05554406· Phase 2· National Cancer Institute (NCI)· Source
Contact: Firas El Chaer (principal investigator)
Recruiting
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
NCT05554393· Phase 2· National Cancer Institute (NCI)· Source
Contact: Firas El Chaer (principal investigator)
Recruiting
HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma
NCT05962242· Phase 2· University of Virginia· Source
Contact: Noah Kalman, M.D.
Recruiting
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390· Phase 2· National Cancer Institute (NCI)· Source
Contact: Firas El Chaer (principal investigator)
Recruiting
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
NCT06048094· Phase 1· Baptist Health South Florida· Source
Contact: Rupesh Kotecha, M.D.
Active, not recruiting
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
NCT05966194· Phase 2· EpicentRx, Inc.· Source
Recruiting
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
NCT05659381· Phase 3· GOG Foundation· Source
Contact: Jacqueline Lebron
Recruiting
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241· Phase 2/3· National Cancer Institute (NCI)· Source
Contact: Rohan Garje (principal investigator)
Active, not recruiting
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
NCT05902169· Phase 3· CarThera· Source
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· Phase 3· LeonaBio· Source
Contact: Ana Sandoval Leon
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· Phase 3· NRG Oncology· Source
Contact: Naomi Dempsey (principal investigator)
Recruiting
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
NCT05673148· Phase 2· Alliance for Clinical Trials in Oncology· Source
Contact: Eric D. Miller, MD, PhD
Recruiting
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768· Phase 3· SWOG Cancer Research Network· Source
Contact: Ana C. Sandoval Leon (principal investigator)
Active, not recruiting
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT05602194· Phase 3· Children's Oncology Group· Source
Recruiting
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NCT05327686· Phase 2· NRG Oncology· Source
Contact: Adeel Kaiser (principal investigator)
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562· Phase 3· Jazz Pharmaceuticals· Source
Contact: Clinical Trial Disclosure & Transparency
Active, not recruiting
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
NCT05546580· Phase 1· Oryzon Genomics S.A.· Source
Active, not recruiting
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
NCT05438212· Phase 3· NRG Oncology· Source
Active, not recruiting
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
NCT05099003· Phase 1/2· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor
NCT04939597· Phase 3· Children's Oncology Group· Source
Recruiting
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
NCT04689048· Phase 1· Baptist Health South Florida· Source
Contact: Rupesh C Kotecha, M.D.
Active, not recruiting
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NCT05095376· Phase 3· NRG Oncology· Source
Active, not recruiting
Pomalidomide Treatment in Patients With Kaposi Sarcoma
NCT04577755· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
NCT04729959· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555· Phase 1/2· Sumitomo Pharma America, Inc.· Source
Contact: SMPA Investigative Site
Active, not recruiting
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04320888· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
NCT03899636· Phase 3· Angiodynamics, Inc.· Source
Active, not recruiting
The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy
NCT04572633· HistoSonics, Inc.· Source
Active, not recruiting
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717· Phase 3· NRG Oncology· Source
Active, not recruiting
Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study
NCT04089358· Phase 3· Children's Oncology Group· Source
Showing 50 of 86.